PsO Pipeline Update: Enrollment Complete in Phase 3 Program of Alumis’ Oral TYK2 Inhibitor
Alumis completed enrollment of more than 1,700 patients in its Phase 3 ONWARD clinical program for ESK-001, a next generation oral tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis.